Opening Session Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Varsha Gandhi, PhD, on Ibrutinib

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Cost of Care

Health-Care Policy

The ASCO Post Staff

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

May

Today In Oncology

Opening Session Panel Discussion

Related Videos

Varsha Gandhi, PhD, on Ibrutinib

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Plasma miR-371a-3p Predicts Recurrence in Stage I Testicular Cancer: Interim Results From the CLIMATE Study

Promising Signal Only ctDNA in Early Breast Cancer Not Yet Ready for Clinical Use

AI Pathology Framework for Biological Understanding of Tumors

AI Model Enables Earlier Detection of Pancreatic Cancer on Routine CT Scans

Breast Density Reduction: Endoxifen vs Tamoxifen